Novartis AG with ticker code (NVS) now have 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 107 and 102 and has a mean target at 104.25. Now with the previous closing price of 87.18 this is indicating there is a potential upside of 19.6%. The 50 day moving average now sits at 90.07 and the 200 moving average now moves to 85.08. The market cap for the company is $182,997m. Find out more information at: https://www.novartis.com
The potential market cap would be $218,828m based on the market concensus.
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
